IN2013MU01920A - - Google Patents

Download PDF

Info

Publication number
IN2013MU01920A
IN2013MU01920A IN1920MU2013A IN2013MU01920A IN 2013MU01920 A IN2013MU01920 A IN 2013MU01920A IN 1920MU2013 A IN1920MU2013 A IN 1920MU2013A IN 2013MU01920 A IN2013MU01920 A IN 2013MU01920A
Authority
IN
India
Prior art keywords
disclosed
conditions
thiazolyl
obesity
cancers
Prior art date
Application number
Other languages
English (en)
Inventor
Kunju Vasu Kamala
Suresh Thacker Pavitra
Anilkumar Sharma Jayesh
Abhiramasundari A
Original Assignee
Kamala K Vasu Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kamala K Vasu Dr filed Critical Kamala K Vasu Dr
Priority to IN1920MU2013 priority Critical patent/IN2013MU01920A/en
Publication of IN2013MU01920A publication Critical patent/IN2013MU01920A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN1920MU2013 2013-05-31 2013-05-31 IN2013MU01920A (enExample)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN1920MU2013 IN2013MU01920A (enExample) 2013-05-31 2013-05-31

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1920MU2013 IN2013MU01920A (enExample) 2013-05-31 2013-05-31

Publications (1)

Publication Number Publication Date
IN2013MU01920A true IN2013MU01920A (enExample) 2015-09-25

Family

ID=54394961

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1920MU2013 IN2013MU01920A (enExample) 2013-05-31 2013-05-31

Country Status (1)

Country Link
IN (1) IN2013MU01920A (enExample)

Similar Documents

Publication Publication Date Title
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
MX2022001105A (es) Anticuerpos anti tigit.
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
GEP201706612B (en) Methods for the treatment of breast cancer
MX2016004678A (es) Composiciones para el tratamiento del cancer.
EP2991670B8 (en) Sobetirome in the treatment of myelination diseases
GB201310909D0 (en) Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
MX2015015249A (es) Peptidos terapeuticos.
PH12015501071A1 (en) Combination therapy of anti-her3 antibodies
LT3065764T (lt) Mini-gastrino analogas, konkrečiai skirtas panaudoti naviko, teigiamo cck2 receptoriaus atžvilgiu, diagnozei ir (arba) gydymui
SI3055331T1 (sl) Konjugirana protitelesa proti LY75 za zdravljenje raka
MX365403B (es) Peptidos y metodos para usarlos.
EP2996721A4 (en) Methods and compositions for prognosis, diagnosis and treatment of adam8-expressing cancer
WO2014197835A3 (en) Methods and compositions for the treatment of cancer
PH12015500169A1 (en) Prediction of treatment response to jak/stat inhibitor
IN2015DN00515A (enExample)
MX2015010023A (es) Anticuerpos anti-cd83 y su uso.
EP3015864A4 (en) Biomarkers for the diagnosis and the response to treatment of pancreatic cancer
PL2943215T3 (pl) Peptydy pochodzące z laktoferycyny do zastosowania w leczeniu nowotworu
PH12016501183A1 (en) Novel compound for treatment of severe hypoglycemia
IS2934B (is) Mólýbden efnasambönd til notkunar við meðferð á sýaníðeitrun
PH12016501184A1 (en) Novel compound for treatment of severe hypoglycemia
PH12016501182A1 (en) Novel compound for treatment of severe hypoglycemia
IN2013MU01920A (enExample)
IN2013MU01918A (enExample)